Business
Oncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer
Oncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYS...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; BORDER-LEFT:black 1pt solid; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n.prntbls{\nBORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid; BORDER-COLLAPSE: collapse; BORDER-TOP: black 1px solid; BORDER-RIGHT: black 1px solid\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer\nCanada NewsWire\nCALGARY, April 14, 2016\n\n\n\n--Intent-to-Treat Analysis Shows Statistically Significant Increase in 2-Year Survival--\n\n\n\nCALGARY, April 14, 2016 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) (\"Oncolytics\" or the \"Company\") today announced updated results for a randomized Phase 2 clinical trial of its lead product, REOLYSIN®, in combination with carboplatin and paclitaxel in patients with pancreatic cancer (NCI-8601). The study is being sponsored by the U.S. National Cancer Institute (\"NCI\"). The update is based on data collected up to January 19, 2016 from the NCI and updates information from previous disclosures by the principal investigator.\n\nUpdate Highlights\n\nOverall survival (\"OS\") of control, test, crossover, and combined test and crossover arms\n\n\n\n\nArm\n\n\nMedian OS(months)\n\n\n1-year OS (%)\n\n\n2-year OS (%)\n\n\n3-year OS (%)\n\n\n\nControl (n = 20)\n\n\n6.57\n\n\n25.0\n\n\n0\n\n\n0\n\n\n\nTest (n = 36)\n\n\n7.33\n\n\n29.6\n\n\n17.7\n\n\n8.87\n\n\n\nCrossover (n = 16)\n\n\n10.97\n\n\n25.0\n\n\n12.5\n\n\n6.25\n\n\n\nCombined Test and Crossover (n = 52)\n\n\n8.73\n\n\n28.1\n\n\n16.0\n\n\n8.02\n\nSource: NCI Clinical Trial Summary: Response Information Report\n\nThe Company performed an intent-to-treat analysis of overall survival on patients with confirmed treatment regi...